Indications of Enoxaparin in Acute Pancreatitis

Risk Assessment for VTE in Acute Pancreatitis

Patients with acute pancreatitis are at increased risk of developing venous thromboembolism due to immobilization 1
Dehydration increases the risk of venous thromboembolism in patients with acute pancreatitis 1, 2
High-risk patients who should receive prophylaxis include those who are unable to mobilize independently 3, 1
Patients with previous history of venous thromboembolism are at high risk and should receive prophylaxis 3, 1
Comorbidities such as cancer increase the risk of venous thromboembolism in patients with acute pancreatitis 3, 1

The standard prophylactic dose of enoxaparin is 40 mg subcutaneously once daily during hospitalization or until the patient is fully ambulatory 4
For patients with severe renal impairment, the dose of enoxaparin should be adjusted to 30 mg subcutaneously once daily 4, 2
For obese patients, intermediate dosing (40 mg subcutaneously every 12 hours) or weight-based dosing (0.5 mg/kg subcutaneously every 12 hours) should be considered 4, 2

VTE prophylaxis should be initiated as soon as the patient is hemodynamically stable 2

VTE prophylaxis should be continued throughout hospitalization or until the patient is fully ambulatory 4
For patients remaining immobile for longer than 30 days, continued prophylaxis is recommended 3, 1

Routine monitoring of anti-Xa levels is not necessary in patients with normal renal function 2
For patients with severe renal impairment receiving prolonged treatment, anti-Xa levels should be monitored with a target of 0.5-1.5 UI/mL 4, 2

Active bleeding is a contraindication for enoxaparin therapy 2
Severe thrombocytopenia is a contraindication for enoxaparin therapy 2
Recent intracranial hemorrhage is a contraindication for enoxaparin therapy 3, 1

Early mobilization and adequate hydration should be encouraged for all acute pancreatitis patients to help prevent VTE 3, 1
The use of anti-embolism stockings alone for VTE prophylaxis is not recommended 3, 1
Combining enoxaparin with intermittent pneumatic compression devices should be considered for patients at very high risk of VTE 5